An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non–small-cell ...

Times between successive events (i.e., gap times) are of great importance in survival analysis. Although many methods exist for estimating covariate effects on gap times, very few existing methods ...

Patients with prostate cancer who were treated with brachytherapy boost showed improved survival compared with those treated with external beam radiotherapy in a recent study. Brachytherapy boost (BTB ...

Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Non–Small-Cell Lung Cancer in the First-Line Setting? In their recent article ...

Hundreds of millions of people live in countries that do not have complete death registration systems, meaning that most deaths are not recorded and that critical quantities, such as life expectancy, ...